News
SDGR
23.34
-2.91%
-0.70
Moderna and OpenAI in pact to fast-track drug development
Healthcare Tech Moderna and OpenAI in pact to fast-track drug development. About 3,000 employees at Massachusetts-based biotech Moderna will have access to AI firm's ChatGPT Enterprise. Moderna has partnered with AI firm OpenAI to deploy the technology across its business.
Seeking Alpha · 1d ago
Weekly Report: what happened at SDGR last week (0415-0419)?
Weekly Report · 3d ago
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Schrödinger, Inc. Granted stock options to nine newly hired employees on April 15, 2024. The company's physics-based computational platform is transforming the way therapeutics and materials are discovered. The stock options have a ten-year term and vest over four years.
Barchart · 04/18 07:30
Analysts See 19% Upside For IJS
NASDAQ · 04/16 10:36
Weekly Report: what happened at SDGR last week (0408-0412)?
Weekly Report · 04/15 09:08
R1 RCM, Health Catalyst downgraded as KeyBanc reviews health-tech space
R1 RCM, Health Catalyst downgraded as KeyBanc Capital Markets downgrades the stocks ahead of Q1 earnings. The firm upgraded GoodRx Holdings and Certara ahead of the healthcare IT space. The analyst cited the recent cybersecurity incident at UnitedHealth's Change Healthcare unit.
Seeking Alpha · 04/10 16:56
Press Release: Schrödinger to Announce First Quarter 2024 Financial Results on May 1
Schrödinger to Announce First Quarter 2024 Financial Results on May 1, 2024. The company will host a conference call and webcast at 4:30 p.m. ET. Schrödinging's physics-based computational platform is transforming the way therapeutics and materials are discovered.
Dow Jones · 04/10 12:31
6 Under-the-Radar AI Stocks That Analysts Expect to Rally
Morgan Stanley lists 6 under-the-radar AI stocks it considers high conviction picks. The company says the market for artificial intelligence is expected to reach a market size of $2.58 trillion by 2032. These are six companies Morgan Stanley believes are worth adding to your portfolio due to the potential of AI.
Barchart · 04/10 08:24
Top buy-rated stocks and sell-rated stocks within Health Care - Citi
Citi Research strategists have lowered the health care sector to underweight. The company has struggled with “uninspiring” growth in equipment and services. Pharmaceuticals, biotechnology and life sciences are the top sell-rated stocks within the sector. The top buy-rated stock is Arcus Biosciences.
Seeking Alpha · 04/04 15:12
Analysts Offer Insights on Healthcare Companies: Staar Surgical (STAA) and Schrodinger (SDGR)
Analysts maintain a Hold rating on Staar Surgical and a Buy rating on Schrodinger. The Healthcare sector has received a lot of coverage today. Needham analyst David Saxon reiterated a hold rating on the company today. The company’s shares closed at $39.07 today.
TipRanks · 04/04 13:10
Analysts Conflicted on These Healthcare Names: Icon (ICLR), Schrodinger (SDGR) and Azenta (AZTA)
Analysts maintain Buy ratings on Icon, Schrodinger and Azenta. Jefferies analyst David Windley maintained a Buy rating on Icon yesterday and set a price target of $385.00. The Healthcare sector has received a lot of coverage today as analysts weigh in on companies in the sector.
TipRanks · 04/04 12:20
32 “Breakthroughs” stocks by BofA - Part 2
Tech 32 “Breakthroughs” stocks by BofA Securities published a list of 32 companies that its analysts believe will benefit from breakthroughs. These 32 stocks have a combined market cap of $16T. The list includes companies in the healthcare, communications, and energy sectors.
Seeking Alpha · 03/21 15:53
Schrödinger Highlights Discovery of SGR-1505, Clinical-Stage MALT1 Inhibitor, at American Chemical Society National Meeting
Schrödinger, Inc. Presented the discovery of SGR-1505, its MALT1 inhibitor, at the American Chemical Society Spring 2024 Meeting. The company is being evaluated in a Phase 1 dose-escalation study in patients with relapsed/refractory B-cell lymphomas. Schrödinging's physics-based computational platform is transforming the way therapeutics and materials are discovered.
Barchart · 03/20 09:27
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Schrödinger, Inc. Granted stock options to six newly hired employees on March 15, 2024. The company's physics-based computational platform is transforming the way therapeutics and materials are discovered. The stock options have a ten-year term and vest over four years.
Barchart · 03/19 07:30
Billionaire Bill Gates Has 35% of His Portfolio Invested in These 2 Artificial Intelligence (AI) Stocks: Are They No-Brainer Buys?
Nearly 35% of the Bill and Melinda Gates Foundation's portfolio is invested in two artificial intelligence stocks. Microsoft and Schrödinger use machine learning to predict molecular structures. Microsoft is a good stock for long-term investors to buy and hold. The company is the sixth-wealthiest individual in the world.
The Motley Fool · 03/18 09:50
Weekly Report: what happened at SDGR last week (0311-0315)?
Weekly Report · 03/18 09:08
High conviction stocks with U.S. productivity opportunities due to AI - MS
Morgan Stanley listed high conviction stocks with U.S. Productivity opportunities due to artificial intelligence. Analysts say companies are in the 'experimental' phase of AI, but will start to benefit from it in 2024. The company listed companies that are early adopters of the technology and could see great changes in productivity.
Seeking Alpha · 03/12 19:08
Weekly Report: what happened at SDGR last week (0304-0308)?
Weekly Report · 03/11 09:08
Weekly Report: what happened at SDGR last week (0226-0301)?
Weekly Report · 03/04 09:08
Schrodinger Is Maintained at Buy by Citigroup
Dow Jones · 03/01 17:33
More
Webull provides a variety of real-time SDGR stock news. You can receive the latest news about Schrodinger, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About SDGR
Schrodinger, Inc. operates a physics-based computational platform that enables the discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. The Company operates through two segments: Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The Company's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor). Its software was used by researchers around the world at more than 1,760 academic institutions.